Related Experiment Video
Updated: Aug 5, 2026

Activation and Measurement of NLRP3 Inflammasome Activity Using IL-1β in Human Monocyte-derived Dendritic Cells
Published on: May 22, 2014
The Microglial NLRP3 Inflammasome in Multiple Sclerosis: Bridging Innate Immunity, Chronic Inflammation, and IFN-β
Prathyusha Koyya1, Hemasundar Alavilli1, Santhi Latha Pandrangi1
1Department of Life Sciences, GITAM School of Science, Gandhi Institute of Technology and Management (Deemed to be University), Visakhapatnam, India.
Abstract:
Background: Multiple sclerosis (MS) is a chronic neurodegenerative and demyelinating disease that is marked by chronic inflammation of the central nervous system (CNS). Although interferon-β (IFN-β) remains one of the pillars of treatment for relapsing-remitting MS (RRMS), inconsistencies in the responses of patients signify the necessity to comprehend the immunopathological processes.Objectives: The NLRP3 (NOD-like receptor family pyrin domain-containing 3) inflammasome, an intracellular signaling platform controlling the activation of caspase-1 and the maturation of interleukin-1β (IL-1β) and interleukin-18 (IL-18) has been of considerable interest among emerging molecular actors. Microglia, the native CNS macrophage, are the center stage of tissue damage and repair.Results: Demyelination and axonal degeneration in neuroinflammation are linked to the role of aberrant activity of the microglial NLRP3 inflammasome. In addition, it is also suggested that an inhibition of inflammasome by IFN-β can be observed in a mechanistic interaction between NLRP3 signaling and response to treatment.Conclusion: In this literature review, the presented data summarize the existing information about the contribution of NLRP3 to the pathogenesis of MS disease, microglial activation, and IFN-β regulation, and how this pathway can be applied to shape personalized treatment approaches.
Insights
The NLRP3 inflammasome plays a key role in multiple sclerosis (MS) pathogenesis and microglial activation. Understanding its interaction with interferon-beta (IFN-β) may improve personalized MS treatments.
Area of Science:
- Neuroimmunology
- Molecular Biology
Background:
- Multiple sclerosis (MS) is a chronic CNS neurodegenerative and demyelinating disease characterized by inflammation.
- Interferon-beta (IFN-β) is a primary treatment for relapsing-remitting MS (RRMS), but patient responses vary, necessitating deeper understanding of immunopathology.
Purpose of the Study:
- To review the role of the NLRP3 inflammasome in MS pathogenesis.
- To explore the connection between NLRP3 inflammasome activity, microglial activation, and IFN-β response in MS.
Main Methods:
- Literature review of existing data on NLRP3 inflammasome, microglia, and IFN-β in MS.
- Analysis of immunopathological mechanisms in MS.
Main Results:
- Aberrant microglial NLRP3 inflammasome activity is linked to demyelination and axonal degeneration in MS.
- IFN-β may inhibit inflammasome activity, suggesting a mechanistic link between NLRP3 signaling and treatment response.
Conclusions:
- The NLRP3 inflammasome is a significant contributor to MS pathogenesis and microglial activation.
- Targeting the NLRP3 inflammasome pathway could offer novel strategies for personalized MS treatment approaches.
Related Concept Videos
Chronic Inflammation: Introduction
Inflammatory Bowel Disease III: Crohn's Disease
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Acute Inflammation I: Inflammatory Response
Inflammatory Response
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...

